A Multi-Center, Open-Label, Clinical Trial to Evaluate the
Safety, Tolerability, and Pharmacokinetics of Sulfatinib in Advanced Solid Tumors and to Evaluate the Anti-tumor Activity and Safety of Sulfatinib in Patients with Advanced Biliary Tract (BTC) and In Patients with Advanced Pancreatic Neuroendocrine Tumors (pNET), NCT02549937
PURPOSE OF THIS CLINICAL RESEARCH TRIAL
To evaluate the safety and tolerability of sulfatinib in patients with advanced solid tumors and to determine the maximum tolerable dose (MTD) or recommended phase II dose (RP2D).
Secondary Objective： To evaluate the pharmacokinetic profile of multiple dose sulfatinib in patients with advanced solid tumors and to evaluate the anti cancer activity of sulfatinib in patients with advanced solid tumors.
MORE INFORMATION ON THIS TRIAL
i2545 / NCT02549937 / Open 9-15-2018